Acyclovir-resistant herpetic keratitis in a solid-organ transplant recipient on systemic immunosuppression
Liam Daniel Turner,1 Peter Beckingsale1,2,3
1Princess Alexandra Hospital; 2Terrace Eye Centre; 3Laser Sight, Brisbane, Queensland, Australia
Purpose: To report a case of acyclovir-resistant herpetic keratitis in a solid-organ lung transplant recipient that was effectively treated with topical trifluridine.
Methods: A case of a 35-year-old female with herpetic epithelial keratitis resistant to acyclovir is described. The patient presented following treatment for 4 weeks with topical acyclovir ointment five times per day and oral valacyclovir 1 g three times per day for herpetic keratitis with no resolution of the epithelial defect or symptoms. Corneal scrapes and swabs were taken for confirmation of the diagnosis and resistance testing. The results were positive for herpes simplex virus 1 and showed acyclovir resistance (inhibitor concentration 90 = 200 µg/mL) and foscarnet sensitivity (inhibitor concentration 90 = 200 µg/mL). The patient was treated with topical trifluridine 2-hourly for 3 weeks and weaned off the drops over the following week.
Results: The patient showed resolution of the epithelial defect, but did have significant corneal toxicity associated with the use of the trifluridine. At 8 weeks, the patient had some stromal shadowing associated with the recent active infection, but symptoms had settled.
Conclusion: This case documents the effective use of topical trifluridine in proven acyclovir-resistant herpetic keratitis. It highlights three things: (1) the importance of considering topical trifluridine as an alternative to topical acyclovir in unresponsive disease; (2) the need to consider solid-organ transplant recipients in the immunocompromised population with resistant herpetic disease, and (3) the need to look for alternatives to treatment of resistant herpetic disease.
Keywords: acyclovir resistance, herpetic keratitis, trifluridine
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Stewart MW, Stewart ML
Published Date: 31 December 2012
Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser
Neubauer AS, Langer J, Liegl R, Haritoglou C, Wolf A, Kozak I, Seidensticker F, Ulbig M, Freeman WR, Kampik A, Kernt M
Published Date: 16 January 2013
Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
Mohamed N, Meyer D
Published Date: 30 January 2013
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
Coffey MJ, DeCory HH, Lane SS
Published Date: 13 February 2013
Scleral buckling with a noncontact wide-angle viewing system in the management of retinal detachment with undetected retinal break: a case report
Kita M, Fujii Y, Kawagoe N, Hama S
Published Date: 21 March 2013
Bakbak B, Ozturk BT, Gedik S, Koktekir BE, Gonul S
Published Date: 26 March 2013
The combination of corneal collagen crosslinking with riboflavin and ultraviolet-a irridation and excimer laser surgery.
Ralla B, Holtmann C, Geerling G
Published Date: 26 March 2013
Published Date: 28 March 2013
Aslanides IM, Mukherjee AN
Published Date: 31 March 2013
Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
Yamamoto A, Okada AA, Sugitani A, Kunita D, Rii T, Yokota R
Published Date: 19 April 2013